Navigation Links
Safinamide Phase III Study Results Presented at 2013 MDS Meeting
Date:6/18/2013

MILAN, June 19, 2013 /PRNewswire/ --


Safinamide significantly improves responder rates in fluctuating Parkinson's disease (PD) patients as add-on to levodopa

Safinamide is associated with clinically important improvement in motor symptoms in fluctuating PD patients as add-on to levodopa

 

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

Results presented showed that in the SETTLE study safinamide significantly improved "super responder" rates in fluctuating PD patients as add-on to levodopa and other dopaminergic therapies. Safinamide was also associated with clinically important improvement in motor symptoms in fluctuating PD patients as add-on to levodopa and other dopaminergic therapies.

Ravi Anand, Newron's CMO, stated: "The results presented indicate a magnitude of benefit with safinamide which is of clinical relevance, i.e. improvements of more than one hour in the patient and caregiver-rated ON and OFF time plus 30 per cent or greater improvement in motor symptoms (UPDRS Part III, as rated by a neurologist) in a significantly (p=0.018) larger proportion of patients than standard of care. These results demonstrate that safinamide produces clinically important improvements even in the more severe patients treated with numerous drugs. Patients who improve by such magnitude in these domains can be referred to as "super responders" and have not been observed with other treatments to d
'/>"/>

SOURCE Newron Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
2. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
3. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
4. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
5. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
6. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
7. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
8. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
9. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
10. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
11. SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015 MEI Pharma, Inc. ... clinical development of novel therapies for cancer, announced today that ... Officer, will present at the 14 th Annual Needham ... Eastern time from the Westin Grand Central Hotel in ... presentation can be accessed at www.meipharma.com . A replay ...
(Date:4/1/2015)... , April 1, 2015  Salix Pharmaceuticals, ... Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX:VRX), ... the outstanding $750,000,000 aggregate principal amount of its ... U8639TAA3 (the " Notes ") pursuant to two ... $262,500,000 aggregate principal amount of the Notes, and ...
(Date:4/1/2015)... April 1, 2015   AMC Health , a ... advances in monitored care that are transforming chronic care ... 2015 Conference. The conference will be held at ... April 12 through 16. In addition to demonstrating its ... AMC Health will share innovations that transform the way ...
Breaking Medicine Technology:MEI Pharma to Present at Needham Healthcare Conference 2Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 2Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 3AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 2AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 3AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 4
... (Otix) (Nasdaq: OTIX ), a leading provider of ... decided to discontinue its operations in Germany as of September ... CEO of Otix stated, "the regulatory obstacles in Germany have ... as a result, we have made the decision to discontinue ...
... announced this week that it has received the Japanese ... collection and transfer of biological samples. The Japanese flocked ... growing number of patents held by COPAN across the ... and transfer of biological samples, including the Australian patent ...
Cached Medicine Technology:Otix Global, Inc. to Discontinue German Operations 2Otix Global, Inc. to Discontinue German Operations 3COPAN Secures Japanese Patent for its Flocked Swab Innovation 2
(Date:4/1/2015)... (PRWEB) April 01, 2015 BioPlus ... innovative specialty pharmacies, has released a new app to ... guidelines for treating chronic hepatitis C virus (HCV) infection. ... based on information from the American Association for the ... sources. , Numerous new direct-acting oral medications to treat ...
(Date:4/1/2015)... Northfield, IL, Bethesda, MD, Alexandria, VA (PRWEB) April ... for Clinical Pathology (ASCP), the College of American ... and the American Society of Clinical Oncology (ASCO) ... guideline on the use of molecular marker testing ... This evidence-based guideline will help establish standard molecular ...
(Date:4/1/2015)... 2015 EAGAN, Minn. (April 1, 2015) ... family of companies (Blue Cross) today announced audited financial ... with net income of $61.5 million, reflecting positive investment ... reported a net operating loss of $8.2 million on ... margin of one-tenth of one percent (0.1%). , ...
(Date:4/1/2015)... SCI Solutions , the health industry’s ... that CEO Joel French will be a featured speaker ... in Chicago, April 12-16, 2015. French will co-present ... Coordination Strategies ” with Northeast Georgia Health System (NGHS) ... than 38,000 healthcare industry professionals are expected at the ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Dr. ... informational seminars in April to discuss the benefits of ... for those suffering from periodontal disease. People who live ... suffer from gum disease can now visit Dr. Stewart, ... traditional gum surgery. With the LANAP® protocol, which is ...
Breaking Medicine News(10 mins):Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 2Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 3Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 4Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 4Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 3
... Alzheimers disease (AD) has lately been suggested to be ... An increasing volume of evidence indicates that AD is ... important markers in tests of given pathophysiological hypotheses. ... Szeged, Hungary, hypothesized that the onset of AD affects ...
... retirement age has revealed that workers who retire early have ... until they reach 65. //This finding disapproves the existing misconception ... and happier lives as a consequence. ,Men were ... women, as were those on lower incomes compared to those ...
... with the outcome of botulinum-a toxin (BTX-A) detrusor ... overactivity. BTX-A detrusor injections have been described in ... spinal cord injury. ,Researchers from Germany ... successfully in children with a neurogenic bladder. After ...
... by Synovate India and sponsored by Colgate-Palmolive (India) Ltd says ... latest toothpaste available in the market, //the level of oral ... surveyed admitted that they have never been to a dentist ... oral hygiene practices are resulting in a myriad of dental ...
... Health Organization survey reveals that currently more than 5.13 ... more and more number of cases being reported each ... hospitals across the country. ,The priority of ... from falling prey to the disease. Inorder to increase ...
... have found that daily gargling with povidione-iodine reduced the chances ... been published in the American Journal of Preventive Medicine. ... the age group of 18 to 65. , ,The ... gargled water with povidone-iodine, the second group gargled with water ...
Cached Medicine News:Health News:Age-Dependent Alterations Not Specific For Alzheimers Disease 2Health News:A New Approach In Treatment Neurogenic Detrusor Overactivity In Children 2Health News:Condom Vending Machines To Be Installed Across Indian States 2Health News:Daily Gargling May Prevent Common Colds 2
... The NexGen Legacy LCCK Femoral ... require additional prosthetic stabilization due to ... function, and require augmentation and/or stem ... The NexGen LCCK is available with ...
... manufacturers focus attention on implant design, one ... Profix Total Knee System seeks to establish ... system and the tools to implant them. ... recognized for innovation in total knee instrumentation, ...
Cruciate retaining, posterior stabilized and constrained components....
Maximum contact. Minimum wear. Outstanding results....
Medicine Products: